Michael Gregory Bell

TL;DR: The structure of a non-peptide agonist, TT-OAD2, bound to the glucagon-like peptide-1 (GLP-1) receptor is solved and alters the understanding of the events that drive the activation of class B receptors.

TL;DR: The above data indicate that LY335979 is an exciting new clinical agent to test the hypothesis that inhibition of P-glycoprotein activity will result in reversal of multidrug resistance in human tumors.

TL;DR: In this paper, a list of pharmaceutical compositions and methods of use for treating dyslipidemia and diseases related to it is presented. But none of them are described in detail.

TL;DR: In this article, a compound of the formula (I): or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising an effective amount of a compound (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly congestive heart disease, hypertension, rheumatoid arthritis or inflammation, comprising administering to a patient in thereof, a patient administered to a user in thereof an effective amounts of the compound of Formula (I).

TL;DR: In this article, selective β3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity were presented in the field of medicine, particularly for Type II diabetic and obesity.